Cellumed Reports 95 Billion KRW in 3Q Cumulative Sales, Up 38% Year-on-Year

[Asia Economy Reporter Hyungsoo Park] Cellumed announced on the 14th that its cumulative consolidated sales for the third quarter reached 95 billion KRW, a 38% increase compared to the same period last year. Due to rising raw material prices and exchange rates, the company recorded an operating loss of 350 million KRW. Net profit for the period was 2.3 billion KRW, maintaining a positive earnings trend.

Demand for the bone graft material certified by the US FDA, 'Rapugen DBM (demineralized bone matrix),' and the dental bone graft material 'Dental Powder,' approved by the Korean Ministry of Food and Drug Safety, has surged, steadily increasing sales in the human tissue segment.

Cellumed also explained that its mRNA production enzyme business is progressing smoothly. Since last year, the company has been conducting research and development with a German firm to produce GMP-grade mRNA production enzymes. Sample production has been completed. They are preparing for full-scale mass production of the production enzymes and conducting sales activities targeting global biopharmaceutical companies.

Based on its technological capabilities related to patient-specific artificial knee joint total replacement surgery (PSI), Cellumed is securing competitiveness in the AI surgical robot field. Since 2020, Cellumed has successfully completed clinical research using PSI in collaboration with major university hospitals such as Seoul National University Hospital and Severance Hospital. This year, the company filed and registered a total of three patents related to the technology. Cellumed is advancing surgical robot software and PSI by integrating AI imaging intelligence technology.

Kang Yongju, Vice President of Cellumed, stated, "With steady sales growth from our subsidiaries and increased exports of the bone graft material 'Rapugen DBM,' dental bone graft material 'Dental Powder,' and cosmeceutical products, we expect to achieve record-high sales this year."

He added, "We will make every effort to prepare for mass production of AI surgical robots and mRNA production enzymes, steadily securing global competitiveness in these sectors."

Furthermore, he introduced, "We will soon disclose plans for business diversification strategies and new business ventures that can enhance stable sales and profitability to maximize shareholder value."

This content was produced with the assistance of AI translation services.